Article focus {#section5-2046-3758.81.BJR-2018-0181.R1}
=============

-   This study investigated the effects of tranexamic acid (TXA) toxicity on human periarticular tissues including tendon, synovium, and cartilage.

Key messages {#section6-2046-3758.81.BJR-2018-0181.R1}
============

-   TXA caused significant periarticular tissue toxicity *ex vivo* and *in vitro* at commonly used clinical concentrations.

-   We suggest clinicians show caution when considering topical TXA treatments, particularly on soft-tissue orthopaedic pro-cedures.

-   Further human clinical trials are required to confirm the safety of TXA before it can be recommended for standard topical practice.

Strengths and limitations {#section7-2046-3758.81.BJR-2018-0181.R1}
=========================

-   While our study shows increased cell death, this may not necessarily translate into poor clinical outcomes to the patient and we recognize that studies evaluating early and longer-term clinical follow-up of topical TXA are required.

Introduction {#section8-2046-3758.81.BJR-2018-0181.R1}
============

Surgeons continually strive to improve post-procedural rehabilitation in their patients, with the hope and intention of enhancing patient satisfaction and surgical outcomes. One such area that has been targeted across the surgical specialties is intra- and postoperative blood loss.^[@bibr1-2046-3758.81.BJR-2018-0181.R1]^ Within orthopaedic surgery, this is particularly relevant in patients undergoing hip and knee arthroplasty, commonly performed procedures that are frequently associated with considerable blood loss.^[@bibr2-2046-3758.81.BJR-2018-0181.R1]^ Postoperative anaemia may predispose patients to an increased risk of cardiopulmonary events and adverse transfusion reactions,^[@bibr3-2046-3758.81.BJR-2018-0181.R1]^ while prolonged hospitalization associated with significant blood loss may result in an increased risk of hospital-acquired infections.^[@bibr4-2046-3758.81.BJR-2018-0181.R1],[@bibr5-2046-3758.81.BJR-2018-0181.R1]^ Ultimately, there may be delayed patient rehabilitation and an escalation in healthcare costs.

Activation of fibrinolysis during and after surgery is a phenomenon considered to contribute significantly to intra- and postoperative blood loss.^[@bibr6-2046-3758.81.BJR-2018-0181.R1]^ Intravenous (IV) administration of the anti-fibrinolytic agent (TXA) is an established off-licence perioperative haemostatic treatment.^[@bibr7-2046-3758.81.BJR-2018-0181.R1]^ Tranexamic acid is a synthetic derivative of the amino acid lysine that inhibits fibrinolysis by competitively blocking the lysine binding site on plasminogen and subsequently inhibiting its conversion to plasmin, a fibrinolytic protease that degrades fibrin clots. It has been shown to reduce postoperative bleeding and blood transfusion requirements in patients undergoing hip and knee arthroplasty.^[@bibr3-2046-3758.81.BJR-2018-0181.R1],[@bibr8-2046-3758.81.BJR-2018-0181.R1]^ Despite its proven benefits, concern remains about the safety of its intravenous administration, given the documented risk of thromboembolic events and acute renal impairment.^[@bibr3-2046-3758.81.BJR-2018-0181.R1],[@bibr9-2046-3758.81.BJR-2018-0181.R1]^

In view of the safety concerns relating to the intravenous administration of TXA, it has been hypothesized that topical administration (intra-/periarticular) may avoid the risks of systemic administration. Recent randomized controlled trials investigating topical administration during hip and knee arthroplasty have demonstrated significantly lower blood loss and transfusion rates in comparison with control groups with no apparent significant systemic side effects.^[@bibr10-2046-3758.81.BJR-2018-0181.R1],[@bibr11-2046-3758.81.BJR-2018-0181.R1]^ Topical TXA solution concentrations have ranged from 10 mg/ml to 200 mg/ml, with application strategies varying between studies.^[@bibr3-2046-3758.81.BJR-2018-0181.R1]^ Most topical administration studies to date have focused primarily on hip and knee arthroplasty, although it is becoming increasingly popular during soft-tissue reconstructions such as anterior cruciate ligament (ACL) reconstruction.^[@bibr12-2046-3758.81.BJR-2018-0181.R1]^ However, unlike the majority of hip and knee arthroplasties, this involves the direct exposure of healthy cartilage, tendon, and ligament to TXA. At present, the interaction between these important periarticular tissues and TXA remains largely unknown, with rodent and human *in vitro* studies on chondrocytes providing conflicting results.^[@bibr13-2046-3758.81.BJR-2018-0181.R1]-[@bibr17-2046-3758.81.BJR-2018-0181.R1]^ Adult tendon and, in particular, cartilage have a poor regenerative capacity and therefore significant damage to these tissues may be devastating to the patient.^[@bibr18-2046-3758.81.BJR-2018-0181.R1],[@bibr19-2046-3758.81.BJR-2018-0181.R1]^

This study was designed to test the hypothesis that TXA had no cytotoxic effects on human periarticular tissues including tendon, synovium, and cartilage.

Materials and Methods {#section9-2046-3758.81.BJR-2018-0181.R1}
=====================

Study design {#section10-2046-3758.81.BJR-2018-0181.R1}
------------

All procedures and protocols were approved by the Ethics Committee under approval number REC14/WS/1035 with informed consent obtained and carried out in accordance with standard operative procedures.

Tissue collection and preparation {#section11-2046-3758.81.BJR-2018-0181.R1}
---------------------------------

Human tendon tissue was harvested during hamstring tendon ACL. Synovial tissue was harvested during total hip arthroplasty (THA) or total knee arthroplasty (TKA). Cartilage tissue was harvested from femoral heads obtained during hip hemiarthoplasty for femoral neck fracture. Tissues were then separated for either *ex vivo* or *in vitro* experiments as outlined below. All patients were screened and excluded if there was a prior history of surgery affecting the same joint, malignancy, or infection. Cartilage was excluded if there was any macroscopic evidence of osteoarthritis, and only Outerbridge grade 0 cartilage was used.^[@bibr20-2046-3758.81.BJR-2018-0181.R1]^

Tissue culture {#section12-2046-3758.81.BJR-2018-0181.R1}
--------------

Human tendon-derived tenocytes were explanted from hamstring tendons and fibroblast-like synoviocytes (FLS) from synovial tissue, as described previously.^[@bibr21-2046-3758.81.BJR-2018-0181.R1]^ Cultures were maintained in a humidified environment at 37°C, 5% CO~2~ in Roswell Park Memorial Institute (RPMI) 1640, supplemented with 10% foetal bovine serum (FBS), 1% penicillin-streptomyocin, and L-glutamine (Life Technologies). Cells were grown to subconfluency and passaged using trypsin ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich, Gillingham, United Kingdom). Cells from the third and fourth passages were seeded two days prior to experimentation and no phenotypic drift was confirmed using polymerase chain reaction (PCR; Scleraxis, Aggregan, SOX9 genes).

Human chondrocytes were isolated by enzymatic digestion of intact femoral head articular cartilage.^[@bibr22-2046-3758.81.BJR-2018-0181.R1]^ Chondrocytes were maintained in Dulbecco\'s modified Eagle\'s medium (DMEM), supplemented with 10% FBS, 1% penicillin-streptomycin, 1% amphotericin, and 10% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). Cells were grown to subconfluency and detached for seeding using Accutase (Sigma-Aldrich). Cells from the initial explantation were not passaged. They were seeded two days prior to experimentation. Tranexamic acid was added to concentrations of 0 mg/ml, 1 mg/ml, 50 mg/ml, or 100 mg/ml. Dilution groups were pH-monitored to ensure effects were not related to acidity.

Confocal microscopy {#section13-2046-3758.81.BJR-2018-0181.R1}
-------------------

Tissue samples were cut into 1 cm^2^ quadruplicate replicate pieces and treated with 0 mg/ml or 100 mg/ml TXA in RPMI, supplemented with 10% FBS and 1% penicillin-streptomycin, at 37°C and 5% CO~2~ for 16 hours. They were then washed in RPMI and stained with 12.5 µM 5-chloromethylfluorescein diacetate (CMFDA) and 10 μMl propidium iodide^[@bibr23-2046-3758.81.BJR-2018-0181.R1]^ for two hours at 37°C, then fixed in 4% formaldehyde. They were imaged using confocal microscopy (LSM 800; Zeiss, Cambridge, United Kingdom), and the proportion of live (green) and dead (red) cells was counted using Imaris x64 (8.4.1) software (Bitplane Ltd, Zurich, Switzerland). Three individual donor tissues were used for the tendon and synovium, and four donors were used for the cartilage tissue.

Cell viability assays {#section14-2046-3758.81.BJR-2018-0181.R1}
---------------------

The *in vitro* effect of TXA at concentrations of 0 mg/ml, 1 mg/ml, 50 mg/ml, and 100 mg/ml over 1, 4, and 24 hours on primary human cell cultures was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assays (Sigma-Aldrich). 2.5 × 10^4^ cells were seeded in each well of a 12-well plate in a volume of 500 μl media per well. Once attached, cells were treated with TXA. Culture medium was aspirated, and sterile-filtered MTT was added to each well. Cells were washed with phosphate-buffered saline (PBS) and incubated with dimethyl sulfoxide (DMSO) for ten minutes to dissolve the formazan product. This was then transferred into a 96-well plate (100 μl per well in duplicate) and read on a microplate reader at 540 nm.

Mitochondrial membrane potential assays {#section15-2046-3758.81.BJR-2018-0181.R1}
---------------------------------------

The mitochondrial membrane potential was measured according to the manufacturer's instructions (DePsipher; R&D Systems, Inc., Minneapolis, Minnesota) by fluorescent microscopy using a fluorescent cationic dye, 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide (JC-1). 5 ×10^4^ cells/well were cultured in 12-well plates for 48 hours in the presence of increasing concentrations of TXA with medium (0 mg/ml, 1 mg/ml, 50 mg/ml, or 100 mg/ml). The cells were then washed with PBS, and reaction buffer was added with DePsipher (5 µl per sample) and stabilizer solution. The cells were incubated at room temperature, in the dark, for a minimum of 15 minutes. The cells were analyzed within one hour by fluorescent microscopy using a fluorescein long-pass filter (EVOS FL Auto 2 Imaging System; Thermo Fisher Scientific, Waltham, Massachusetts). Using this system, cells undergoing apoptosis should appear green (585/590 nm), while healthy cells appear red (510/527 nm). Four corner random field images were saved and the number of apoptotic (green) and live (red) cells counted per image. The percentage of apoptotic cells as a proportion of total cells was calculated for each image and the mean percentage calculated for each sample.

Cellular apoptosis {#section16-2046-3758.81.BJR-2018-0181.R1}
------------------

Multi-apoptotic protein detection arrays (Human Apoptosis Antibody Array Kit; R&D Systems, Inc.) were used to determine possible apoptotic pathways involved in cell death according to the manufacturer's instructions. Cells were treated with 0 mg/ml, 1 mg/ml, 50 mg/ml, or 100 mg/ml TXA for one hour. The protein content of each well was quantified using a Micro bicinchoninic acid assay (BCA) Protein Assay Kit (Thermo Fisher Scientific) and read on a microplate reader at 540 nm. Lysate protein concentrations were then normalized in lysis buffer. Cells were cultured in 12-well plates for one hour, with increasing concentrations of TXA with medium (0 mg/ml, 1 mg/ml, 50 mg/ml, or 100 mg/ml). Cell supernatants were aspirated and discarded. After blocking of non-specific binding at room temperature for one hour, antibody array membranes were incubated with the cell lysate (1.5 ml) at 4°C overnight and then with a diluted solution of horseradish peroxidase (HRP)-conjugated streptavidin at room temperature for 30 minutes. Visualization of protein expression was carried out by chemiluminescence and signal intensity was quantified using Luminex (Azure c500; Azure Biosystems, Dublin, California). The immunoreactive band density was analyzed using WinImage studio version 5.2 (LI-COR Biosciences, Lincoln, Nebraska).

Statistical analysis {#section17-2046-3758.81.BJR-2018-0181.R1}
--------------------

All results are shown as mean ± standard error of the mean, and all statistical analysis was performed using Student's paired *t*-test or analysis of variance (ANOVA) test with Dunnett's *post hoc* analysis, as shown in the figures, using the GraphPad Prism 5 software (GraphPad Software, San Diego, California). A p-value of \< 0.05 was considered statistically significant.

Results {#section18-2046-3758.81.BJR-2018-0181.R1}
=======

Tranexamic acid toxicity in periarticular tissues *ex vivo* {#section19-2046-3758.81.BJR-2018-0181.R1}
-----------------------------------------------------------

We first investigated whether *ex vivo* tissues (n = 3 tendon, synovium; n = 4 cartilage) treated with TXA displayed evidence of cytotoxicity. Treatment with 100 mg/ml of TXA for 16 hours caused a significant increase in cell death within tendon, synovium, and cartilage tissues compared with control ([Fig. 1](#fig1-2046-3758.81.BJR-2018-0181.R1){ref-type="fig"} and [Table I](#table1-2046-3758.81.BJR-2018-0181.R1){ref-type="table"}).

![Tranexamic acid (TXA) toxicity in periarticular tissues *ex vivo*. a) Percentage of dead cells in control (0 mg/ml) and TXA-treated (100 mg/ml) cells in each periarticular tissue (n = 3 tendon, synovium; n = 4 cartilage) after 16 hours of treatment. Mean ± standard error of the mean; Student's paired *t*-test. †p \< 0.01. b) Tendon, synovium, ligament, and cartilage tissue imaged by confocal microscopy with 5-chloromethylfluorescein diacetate (CMFDA) and propidium iodide (PI) stain at 16 hours of treatment in control and TXA-treated (100 mg/ml TXA cells). Green stained cells counted as live and red stained cells counted as dead.](bonejointres-08-11-g001){#fig1-2046-3758.81.BJR-2018-0181.R1}

###### 

Numerical representation of the data shown in [Figure 1](#fig1-2046-3758.81.BJR-2018-0181.R1){ref-type="fig"}

              0 mg/ml       100 mg/ml   p-value           
  ----------- ------------- ----------- ------------- --- -------
  Cartilage   5.5 (4.1)     4           65.0 (14.3)   4   0.005
  Tendon      65.0 (4.5)    3           96.3 (3.2)    3   0.002
  Synovium    18.0 (11.1)   3           66.0 (1.0)    3   0.02

Tranexamic acid toxicity *in vitro* {#section20-2046-3758.81.BJR-2018-0181.R1}
-----------------------------------

Following *ex vivo* experiments, we performed time and dose curves to determine the concentration and duration of exposure to TXA at which a significant reduction in cell viability occurred. MTT assays measuring cell metabolic activity acted as an indirect measurement of cell viability. A significant fall in cell viability occurred in all cell types at higher doses over a four-hour duration or low concentrations following 24 hours of treatment.

Tenocyte viability was significantly reduced when treated with TXA at 100 mg/ml for four hours ([Fig. 2](#fig2-2046-3758.81.BJR-2018-0181.R1){ref-type="fig"}). Additionally, concentrations of 1 mg/ml, 50 mg/ml, or 100 mg/ml of TXA for 24 hours also caused a significant reduction in cell viability. Fibroblast-like synoviocyte viability was significantly reduced when treated with TXA at 1 mg/ml, 50 mg/ml, or 100 mg/ml for four hours and 50 mg/ml or 100 mg/ml for 24 hours ([Fig. 2](#fig2-2046-3758.81.BJR-2018-0181.R1){ref-type="fig"}). Furthermore, chondrocyte viability was significantly reduced when treated with TXA at 100 mg/ml for four hours and 50 mg/ml or 100mg/ml for 24 hours. There were no significant differences at one hour or with lower concentrations of TXA.

![Tranexamic acid (TXA) toxicity *in vitro*. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay of: a) to c) tenocyte (n = 11); d) to f) fibroblast-like synoviocyte (FLS; n = 5); and g) to i) chondrocyte (n = 5) viability at: a), d), g) one; b), e), h) four; and c), f), i) 24 hours. Values were measured as luminescence and expressed as percentage change from untreated (control) wells. \*p \< 0.05; †p \< 0.01; ‡p \< 0.001. Data are means ± standard error of the mean; one-way analysis of variance; Dunnett's Multiple Comparison Test.](bonejointres-08-11-g002){#fig2-2046-3758.81.BJR-2018-0181.R1}

Cellular death {#section21-2046-3758.81.BJR-2018-0181.R1}
--------------

We subsequently measured mitochondrial membrane potential as a direct measure of cellular death (apoptosis, [Fig. 3](#fig3-2046-3758.81.BJR-2018-0181.R1){ref-type="fig"}). Tenocyte apoptosis was significantly increased when cells were treated with 100 mg/ ml for one hour or 50 mg/ml to 100 mg/ml TXA for four hours. Fibroblast-like synoviocyte and chondrocyte cell apoptosis was significantly increased when cells were exposed to 50 mg/ml or 100 mg/ml for one hour and 100 mg/ml for four hours.

![Tranexamic acid (TXA)-associated periarticular apoptosis. Percentage of: a) and b) tenocyte (n = 3); c) and d) fibroblast-like synoviocyte (FLS; n = 3); and e) and f) chondrocyte (n = 4) death at a), c), e) one and b), d), f) four hours with 0 mg/ml, 1 mg/ml, 50 mg/ml, or 100 mg/ml TXA treatment. Dying cells (green) were calculated as a proportion of healthy (red) cells. \*p \< 0.05; †p \< 0.01. Data represent mean ± standard error of the mean; one-way analysis of variance; Dunnett's Multiple Comparison Test. g) Fluorescent microscopy images show tenocytes, FLS, and chondrocytes at: one hour, 0 mg/ml TXA; one hour, 100 mg/ml TXA; and four hours, 100 mg/ml TXA.](bonejointres-08-11-g003){#fig3-2046-3758.81.BJR-2018-0181.R1}

Multi-protein apoptotic arrays {#section22-2046-3758.81.BJR-2018-0181.R1}
------------------------------

As fluorescent microscopy identified increased cell death at one and four hours, we carried out single-sample, multi-protein, apoptotic arrays to identify potential mechanisms that may be involved ([Fig. 4](#fig4-2046-3758.81.BJR-2018-0181.R1){ref-type="fig"}). Treatment with 0 mg/ml, 1 mg/ml, 50 mg/ml, and 100 mg/ml of TXA for one hour caused an increase in apoptotic protein expression in tenocytes (pro caspase-3, cleaved caspase-3, Catalase, heat shock protein (HSP) 27, FLS cells (X-linked inhibitor of apoptosis protein (XIAP), Survivin, cellular inhibitor of apoptosis protein (cIAP), HSP27, Catalase, heme oxygenase 1 (HO-1), HSP70 and HSP60, cleaved and pro caspase-3) and chondrocytes (HO-2, Phosphorad-17, hypoxia-inducible factor 1-alpha (HIF1-α), cleaved and pro caspase-3). This suggests that TXA-mediated cell death may be orchestrated in part via a caspase-3-dependent apoptotic mechanism across all cell types.

![a) Tranexamic acid (TXA)-associated periarticular apoptosis pathways. Caspase-3 activation induced by tranexamic acid *in vitro* in periarticular tissues: b) and c) tenocyte; d) and e) fibroblast-like synoviocyte (FLS); and f) and g) chondrocyte single-sample multi-protein apoptotic arrays. b), d), f) Pro caspase-3 and c), e), g) cleaved caspase-3 samples were treated with 0 mg/ml, 1 mg/ml, 50 mg/ml, or 100 mg/ml of TXA for one hour. Pro and cleaved forms of caspase-3 signal pixel density plotted relative to control spots. HSP, heat shock protein; XIAP, X-linked inhibitor of apoptosis protein; cIAP, cellular inhibitor of apoptosis protein; HO-1, heme oxygenase 1; HIF1-α, hypoxia-inducible factor 1-alpha.](bonejointres-08-11-g004){#fig4-2046-3758.81.BJR-2018-0181.R1}

Discussion {#section23-2046-3758.81.BJR-2018-0181.R1}
==========

Our study provides evidence of TXA cytotoxicity to human periarticular tissues *ex vivo* and *in vitro* at concentrations and durations of treatment routinely used in a clinical environment. Human tendon, synovium, and cartilage tissues all showed significantly higher rates of cell death when treated with TXA over a clinically relevant time period when considering the tissue half-life of TXA following IV administration.^[@bibr6-2046-3758.81.BJR-2018-0181.R1]^

The use of TXA as an intravenous haemostatic agent during hip and knee arthroplasty is well established, with proven benefits in reduction of peri- and postoperative blood loss.^[@bibr3-2046-3758.81.BJR-2018-0181.R1],[@bibr6-2046-3758.81.BJR-2018-0181.R1]^ Increasingly, its use is being expanded to topical application in orthopaedic surgical procedures,^[@bibr23-2046-3758.81.BJR-2018-0181.R1]-[@bibr25-2046-3758.81.BJR-2018-0181.R1]^ which has been shown to deliver similar outcomes postoperatively to those of intravenous administration.^[@bibr11-2046-3758.81.BJR-2018-0181.R1],[@bibr26-2046-3758.81.BJR-2018-0181.R1]-[@bibr29-2046-3758.81.BJR-2018-0181.R1]^ Furthermore, its utilization has now expanded into topical application during soft-tissue surgery including arthroscopic ACL reconstruction.^[@bibr30-2046-3758.81.BJR-2018-0181.R1],[@bibr31-2046-3758.81.BJR-2018-0181.R1]^ There are various methods of topical administration described in the literature, including, but not limited to, pre- or postoperative injection, intraoperative wash, postoperative intra-articular infusion through a surgical drain, and direct tissue impregnation.^[@bibr11-2046-3758.81.BJR-2018-0181.R1],[@bibr28-2046-3758.81.BJR-2018-0181.R1],[@bibr29-2046-3758.81.BJR-2018-0181.R1],[@bibr32-2046-3758.81.BJR-2018-0181.R1]-[@bibr36-2046-3758.81.BJR-2018-0181.R1]^ Most literature describes the administration of between 10 mg/ml and 100 mg/ml of TXA; however, significantly larger doses have been reported.^[@bibr33-2046-3758.81.BJR-2018-0181.R1]^ Indeed, treatment with high-dose TXA (100 mg/ml) into tissues or a closed joint space may result in concentrations remaining within the synovial fluid and tissues^[@bibr36-2046-3758.81.BJR-2018-0181.R1]^ of over 1 mg/ml at up to 24 hours or longer. Our findings suggest that caution should be used when considering exposing periarticular tissues to TXA either at high concentrations or for durations even as short as one hour. The practice of intra-articular injection or infusion, prolonged surgical soaking, or tissue impregnation, particularly when into an enclosed joint or space, should be undertaken with the knowledge of the current study and other studies that show increased cell death.

Previous studies investigating TXA cytotoxicity to resident periarticular tissues have produced variable results depending on animal *versus* human tissue and dosing regime utilized.^[@bibr13-2046-3758.81.BJR-2018-0181.R1]-[@bibr17-2046-3758.81.BJR-2018-0181.R1]^ Tuttle et al^[@bibr17-2046-3758.81.BJR-2018-0181.R1]^ found that treatment with 100 mg/ml of TXA was cytotoxic to bovine cartilage explants, and 50 mg/ml to murine chondrocytes from as early as eight hours. Ambra et al^[@bibr14-2046-3758.81.BJR-2018-0181.R1]^ treated porcine cartilage explants with 0 mg/ml to 4 mg/ml of TXA for up to six hours and found no significant increase in cytotoxicity with live/dead cell staining and confocal microscopy. Sitek et al^[@bibr13-2046-3758.81.BJR-2018-0181.R1]^ found no obvious effect on human chondrocyte culture within gel grafts when grown in culture media containing 10 mg/ml or 20 mg/ml of TXA. More recently, Parker et al^[@bibr16-2046-3758.81.BJR-2018-0181.R1]^ described cytotoxicity in human chondrocytes *in vivo* and cartilage explants *ex vivo* at concentrations over 20 mg/ml at 12 hours' exposure. We noted decreased cell viability in tenocytes, FLS, and chondrocytes when exposed to high concentrations (100 mg/ml) over an intermediate duration (four hours), but also even at the lowest concentration (1 mg/ml) over a longer duration (24 hours). Furthermore, our study directly addresses the mechanism underlying TXA-induced cell death whereby we implicate caspase-dependent apoptosis.

There are limitations inherent in our study. None of our experiments take into account the TXA being washed away *in vivo*; the joint space is a dynamic environment and other cell types (e.g. inflammatory cells and platelets) could potentially have a role in TXA clearance. We do, however, know that the half-life of TXA in a closed joint following intravenous administration is around three hours and thus we feel confident that our *in vitro* experiments are representative.

With our *ex vivo* model, we had a high percentage of cell death in our tendon control. This is likely due to the effect of tissue drying between surgical harvesting and completion of graft preparation. However, this may actually mask the true extent of TXA toxicity in tendon tissue. It may also have been beneficial to study the *ex vivo* effects of TXA at additional timepoints and TXA concentrations, as was carried out with our *in vitro* experimentation. In addition, we acknowledge that age-related degenerative changes may have had an influence on cell viability with regard to the synovium/cartilage obtained at THA/TKA, as they were from older patients but were constrained by our local ethics consent for obtaining tissue samples. While the current study shows increased cell death, this may not necessarily translate into poor clinical outcomes to the patient, and we recognize that studies evaluating early and longer-term clinical follow-up of topical TXA-treated patients, particularly in soft-tissue orthopaedic surgery, should be undertaken in order to understand the translational potential of this basic science study.

On the basis of our findings, we would suggest that clinicians should show caution when considering topical TXA treatments, particularly on soft-tissue orthopaedic procedures. There is a need for further human clinical trials in order to clarify the safety of this before it can be recommended for standard topical practice.
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